Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion
NASDAQ:IBRX

ImmunityBio (IBRX) Stock Price, News & Analysis

ImmunityBio logo
$8.22 -0.09 (-1.08%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$8.27 +0.05 (+0.60%)
As of 10/23/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About ImmunityBio Stock (NASDAQ:IBRX)

Advanced

Key Stats

Today's Range
$8.05
▼
$8.35
50-Day Range
$7.58
▼
$10.51
52-Week Range
$1.95
▼
$12.43
Volume
5.93 million shs
Average Volume
16.12 million shs
Market Capitalization
$8.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00
Consensus Rating
Moderate Buy

Company Overview

ImmunityBio, Inc. is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune response against cancer and infectious diseases. The company’s approach combines immune-system modulators, cellular therapies, vaccines and other technologies intended to address multiple stages of the disease-treatment process.

Its lead product, Anktiva (nogapendekin alfa inbakicept-pmln, also known as N-803), is an interleukin-15 receptor agonist designed to stimulate natural killer cells and T cells. In the United States, Anktiva is approved for use with Bacillus Calmette-Guérin in certain adults with BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. ImmunityBio is also evaluating Anktiva and related therapies in additional cancer indications and treatment combinations.

The company’s broader pipeline includes investigational therapies intended to support cancer immunotherapy, cellular immune responses and vaccine development. ImmunityBio was formed through the combination of ImmunityBio and NantKwest, completed in 2021, bringing together complementary immunotherapy platforms. The company is headquartered in California and was founded by Patrick Soon-Shiong, who serves as its executive chairman and has played a central role in its scientific and corporate direction.

AI Generated. May Contain Errors.

ImmunityBio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

IBRX MarketRank™: 
3.397263948495 of 5 stars

ImmunityBio scored higher than 68% of companies evaluated by MarketBeat, and ranked 230th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ImmunityBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    ImmunityBio has a consensus price target of $16.00, representing about 94.6% upside from its current price of $8.22.

  • Amount of Analyst Coverage

    ImmunityBio has only been the subject of 4 research reports in the past 90 days.

  • Read more about ImmunityBio's stock forecast and price target.
  • Earnings Growth

    Earnings for ImmunityBio are expected to grow in the coming year, from ($0.30) to ($0.11) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ImmunityBio is -8.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ImmunityBio is -8.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about ImmunityBio's valuation and earnings.
  • Percentage of Shares Shorted

    34.54% of the float of ImmunityBio has been sold short.
  • Short Interest Ratio / Days to Cover

    ImmunityBio has a short interest ratio ("days to cover") of 8.88.
  • Change versus previous month

    Short interest in ImmunityBio has recently decreased by 1.05%, indicating that investor sentiment is improving.
  • Dividend Yield

    ImmunityBio does not currently pay a dividend.

  • Dividend Growth

    ImmunityBio does not have a long track record of dividend growth.

  • News Sentiment

    ImmunityBio has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for ImmunityBio this week, compared to 9 articles on an average week.
  • Search Interest

    49 people have searched for IBRX on MarketBeat in the last 30 days. This is an increase of 123% compared to the previous 30 days.
  • MarketBeat Follows

    20 people have added ImmunityBio to their MarketBeat watchlist in the last 30 days. This is an increase of 82% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ImmunityBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,119,838.00 in company stock.

  • Percentage Held by Insiders

    66.10% of the stock of ImmunityBio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    8.58% of the stock of ImmunityBio is held by institutions.

  • Read more about ImmunityBio's insider trading history.
Receive IBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunityBio and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IBRX Stock News Headlines

Elon Musk’s Hushed FCC Filing. Dec 8th.
Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly.tc pixel
Comparing ImmunityBio (NASDAQ:IBRX) and eXoZymes (NASDAQ:EXOZ)
FY2028 EPS Estimates for ImmunityBio Raised by HC Wainwright
See More Headlines

IBRX Stock Analysis - Frequently Asked Questions

ImmunityBio's stock was trading at $1.98 at the start of the year. Since then, IBRX stock has increased by 315.2% and is now trading at $8.22.

ImmunityBio, Inc. (NASDAQ:IBRX) posted its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.14. The firm earned $51.24 million during the quarter, compared to analysts' expectations of $49.70 million.

ImmunityBio (IBRX) raised $205 million in an IPO on Tuesday, July 28th 2015. The company issued 9,531,200 shares at $20.00-$23.00 per share.

Top institutional investors of ImmunityBio include Kercheville Advisors LLC (0.06%), Doliver Advisors LP (0.02%), SBI Securities Co. Ltd. (0.02%) and Collective Family Office LLC (0.02%). Insiders that own company stock include Barry J Simon, Cheryl Cohen and Christobel Selecky.
View institutional ownership trends
.

Shares of IBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunityBio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Tesla (TSLA), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA) and Super Micro Computer (SMCI).

Company Calendar

Last Earnings
8/04/2026
Today
10/25/2026
Next Earnings (Estimated)
11/03/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IBRX
CIK
1326110
Fax
N/A
Employees
691
Year Founded
2014

Price Target and Rating

High Price Target
$23.00
Low Price Target
$12.00
Potential Upside/Downside
+94.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.97)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$351.40 million
Net Margins
-598.55%
Pretax Margin
-598.69%
Return on Equity
N/A
Return on Assets
-51.65%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.72
Quick Ratio
5.70

Sales & Book Value

Annual Sales
$165.79 million
Price / Sales
52.55
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.51) per share
Price / Book
-16.12

Miscellaneous

Outstanding Shares
1,059,836,000
Free Float
359,284,000
Market Cap
$8.71 billion
Optionable
Optionable
Beta
0.02

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NASDAQ:IBRX) was last updated on 10/23/2026 by MarketBeat.com Staff.
From Our Partners